Eli Lilly to Enter Targeted Radioligand Therapy with $1.4 Billion Acquisition of Point Biopharma

On October 3, Eli Lilly announced that it would acquire biopharmaceutical company POINT Biopharma Global for $1.4 billion (over 10.2 billion yuan), marking Eli Lilly's official entry into the field of targeted radiopharmaceutical cancer treatment (radionuclide-drug conjugates). Eli Lilly will acquire all outstanding shares of POINT at $12.50 per share, with a total value of $1.4 billion. The transaction has been approved by the boards of both companies and is expected to be completed by the end of this year, subject to customary closing conditions.